- POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition
- Results garnered from company’s HSC optimization are unparalleled in field
- Soluble Biotech lands first major contract, signifying major company milestone
Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, POAI, through its subsidiary Soluble Biotech, delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations.
HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/vbZ53). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased solubility and physical stability of proteins. And while the technology produces unparalleled optimization results, it provides other benefits as well.
Using current methods, optimization can take more than a year, cost hundreds of thousands of dollars and require teams of five or more individuals to complete. Optimization with HSC, on the other hand, takes only three months, costs tens of thousands of dollars, and needs just one individual to conduct. The comparison is stark — and irresistible. Soluble Biotech has already finalized its first substantial contract since being acquired by POAI earlier this year and is currently negotiating additional contracts (https://ibn.fm/rZyMr).
“Our first contract is a major milestone and validates our recent move into a new, larger facility,” said Soluble Biotech founder Dr. Larry DeLucas, who is also a former NASA astronaut. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies.”
A provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes, Soluble Biotech is fast becoming recognized for its expertise in enhancing the drug-development process by rapidly optimizing protein solubility and stability. The company brings proprietary transformational technology to formulation development for protein-based pharmaceuticals and vaccines. In addition, its solubilization and stability technology is used at academic, pharmaceutical and government laboratories involved in conducting fundamental protein research.
Soluble Biotech’s exclusive HSC technology was developed by Dr. William Wilson, a former chairman of the chemistry department at Mississippi State University, and DeLucas; the two have spent almost 20 years developing the game-changing technology and tool. HSC has been validated over the past decade through numerous industry and academic collaborations with several clients seeing tenfold and even hundredfold increases in their protein’s solubility while also maintaining physical stability. For the pharmaceutical sector, this means faster development times and quicker progression of molecules into the clinic. In academics, these results lead to further progression of biochemical and biology studies that are vital to advance fundamental research in areas of unmet medical need.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
